12‐month primary patency rates of contemporary endovascular device therapy for femoro‐popliteal occlusive disease in 6,024 patients: Beyond balloon angioplasty

Marmagkiolis, Konstantinos; Hakeem, Abdul; Choksi, Nishit; Al‐Hawwas, Malek; Edupuganti, Mohan Mallikarjuna Rao; Leesar, Massoud A.; Çilingiroğlu, Mehmet

doi:10.1002/ccd.25510

Cited by 36 publications

(17 citation statements)

References 59 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A wide range of percutaneous therapies using a variety of endovascular devices, including percutaneous transluminal angioplasty (PTA), atherectomy, and stent placement, have been used; however, 5-year results are confined to isolated reports. 1 – 5 …”

mentioning

confidence: 99%

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery

et al. 2016

View full text Add to dashboard Cite

Background—This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS.Methods and Results—Patients with symptomatic femoropopliteal artery disease were randomly assigned to DES (n=236) or PTA (n=238). Approximately 91% had claudication; 9% had critical limb ischemia. Patients experiencing acute PTA failure underwent secondary randomization to provisional BMS (n=59) or DES (n=61). The 1-year primary end points of event-free survival and patency showed superiority of primary DES in comparison with PTA; these results were sustained through 5 years. Clinical benefit (freedom from persistent or worsening symptoms of ischemia; 79.8% versus 59.3%, P<0.01), patency (66.4% versus 43.4%, P<0.01), and freedom from reintervention (target lesion revascularization, 83.1% versus 67.6%, P<0.01) for the overall DES group were superior to standard care in nonrandomized comparisons. Similarly, clinical benefit (81.8% versus 63.8%, P=0.02), patency (72.4% versus 53.0%, P=0.03), and freedom from target lesion revascularization (84.9% versus 71.6%, P=0.06) with provisional DES were improved over provisional BMS. These results represent >40% relative risk reduction for restenosis and target lesion revascularization through 5 years for the overall DES in comparison with standard care and for provisional DES in comparison with provisional BMS.Conclusions—The 5-year results from this large study provide long-term information previously unavailable regarding endovascular treatment of femoropopliteal artery disease. The Zilver PTX DES provided sustained safety and clinical durability in comparison with standard endovascular treatments.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00120406.

show abstract

mentioning

confidence: 99%

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The different endovascular devices include cryo‐balloons, excimer laser atherectomy, siverwalk atherectomy, and drug coated balloons. In a pooled analysis the 12 month patency rates were 60.7%, 51.1%, 63.5%, and 78.2%, respectively . However, there are no randomized studies looking in their effectiveness in treating AVF.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Cutting Balloon Angioplasty and Percutaneous Balloon Angioplasty of Arteriovenous Fistula Stenosis: A Meta‐Analysis and Systematic Review of Randomized Clinical Trials

Agarwal¹,

Nadkarni

Yacoub

et al. 2015

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…While some preventative medications exist, invasive procedures such as angioplasty, stenting, and bypass surgery are often required to restore blood vessel patency. However, these procedures provide only temporary solutions; it is estimated that up to 15–50% of angioplasties, 16–30% of saphenous vein bypass grafts, and up to 90% of synthetic coronary bypass grafts fail within 1–3 years ( Lemson et al, 2000 ; Goldman et al, 2011 ; Kennealey et al, 2011 ; Siracuse et al, 2012 ; Marmagkiolis et al, 2014 ). Other vascular diseases such as aneurysm cannot currently be prevented or treated with medication, and must be surgically repaired.…”

Section: Introductionmentioning

confidence: 99%

Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering

et al. 2018

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of death in the United States. Treatment often requires surgical interventions to re-open occluded vessels, bypass severe occlusions, or stabilize aneurysms. Despite the short-term success of such interventions, many ultimately fail due to thrombosis or restenosis (following stent placement), or incomplete healing (such as after aneurysm coil placement). Bioactive molecules capable of modulating host tissue responses and preventing these complications have been identified, but systemic delivery is often harmful or ineffective. This review discusses the use of localized bioactive molecule delivery methods to enhance the long-term success of vascular interventions, such as drug-eluting stents and aneurysm coils, as well as nanoparticles for targeted molecule delivery. Vascular grafts in particular have poor patency in small diameter, high flow applications, such as coronary artery bypass grafting (CABG). Grafts fabricated from a variety of approaches may benefit from bioactive molecule incorporation to improve patency. Tissue engineering is an especially promising approach for vascular graft fabrication that may be conducive to incorporation of drugs or growth factors. Overall, localized and targeted delivery of bioactive molecules has shown promise for improving the outcomes of vascular interventions, with technologies such as drug-eluting stents showing excellent clinical success. However, many targeted vascular drug delivery systems have yet to reach the clinic. There is still a need to better optimize bioactive molecule release kinetics and identify synergistic biomolecule combinations before the clinical impact of these technologies can be realized.

show abstract

12‐month primary patency rates of contemporary endovascular device therapy for femoro‐popliteal occlusive disease in 6,024 patients: Beyond balloon angioplasty

Cited by 36 publications

References 59 publications

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery

Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery

Comparison of Cutting Balloon Angioplasty and Percutaneous Balloon Angioplasty of Arteriovenous Fistula Stenosis: A Meta‐Analysis and Systematic Review of Randomized Clinical Trials

Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering

Contact Info

Product

Resources

About